Induction-related cost of patients with acute myeloid leukaemia in France. - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Int J Clin Pharm Année : 2011

Induction-related cost of patients with acute myeloid leukaemia in France.

Résumé

OBJECTIVE: The economic profile of acute myeloid leukaemia (AML) is badly known. The few studies published on this disease are now relatively old and include small numbers of patients. The purpose of this retrospective study was to evaluate the induction-related cost of 500 patients included in the AML 2001 trial, and to determine the explanatory factors of cost. SETTING: "Induction" patient's hospital stay from admission for "induction" to discharge after induction. METHOD: The study was performed from the French Public Health insurance perspective, restrictive to hospital institution costs. The average management of a hospital stay for "induction" was evaluated according to the analytical accounting of Besançon University Teaching Hospital and the French public Diagnosis-Related Group database. Multiple linear regression was used to search for explanatory factors. MAIN OUTCOME MEASURE: Only direct medical costs were included: treatment and hospitalisation. RESULTS: Mean induction-related direct medical cost was estimated at €41,852 ± 6,037, with a mean length of hospital stay estimated at 36.2 ± 10.7 days. After adjustment for age, sex and performance status, only two explanatory factors were found: an additional induction course and salvage course increased induction-related cost by 38% (± 4) and 15% (± 1) respectively, in comparison to one induction. These explanatory factors were associated with a significant increase in the mean length of hospital stay: 45.8 ± 11.6 days for 2 inductions and 38.5 ± 15.5 if the patient had a salvage course, in comparison to 32.9 ± 7.7 for one induction (P < 10⁻⁴). This result is robust and was confirmed by sensitivity analysis. CONCLUSION: Consideration of economic constraints in health care is now a reality. Only the control of length of hospital stay may lead to a decrease in induction-related cost for patients with AML.

Domaines

Cancer

Dates et versions

hal-00849659 , version 1 (31-07-2013)

Identifiants

Citer

Virginie Nerich, Bruno Lioure, Maryline Rave, Christian Recher, Arnaud Pigneux, et al.. Induction-related cost of patients with acute myeloid leukaemia in France.. Int J Clin Pharm, 2011, 33 (2), pp.191-9. ⟨10.1007/s11096-010-9462-1⟩. ⟨hal-00849659⟩
1417 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More